Drug Recall: Simvastatin 5 mg tablets due to manufacturing compliance violations
Direct Rx is recalling 51 bottles of Simvastatin 5 mg tablets nationwide due to Good Manufacturing Practice deviations. The recall is voluntary and was initiated in March 2023.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II recall for manufacturing compliance violations with no reported illnesses or injuries. The rubric classifies voluntary precautionary recalls without reported harm as Moderate (score 2).
Plain-English summary
Direct Rx is recalling Simvastatin, USP, 5 mg tablets in 90-count bottles with National Drug Code (NDC) 61919-0710-90 due to Good Manufacturing Practice (cGMP) deviations. The recall affects 51 bottles that were distributed nationwide in the United States.
The affected lot numbers are 03JA2209, 28FE2225, 28AP2211, and 07AP2203, with an expiration date of June 30, 2023. The FDA classified this as a Class II recall on March 24, 2023. The recall was initiated by Direct Rx on March 13, 2023, on a voluntary basis and was terminated on June 17, 2024.
The recalled product
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot
- expiry: 03JA2209
- 28FE2225
- 28AP2211
- 07AP2203
- exp 6/30/23
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 11 recalled by Direct Rx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same manufacturer · Direct Rx
See all →- ModerateDuloxetine 30 mg capsules recalled for impurity above FDA limits
FDA (Drugs) · 2026-07-01
- HighDuloxetine delayed-release capsules exceed the interim nitrosamine impurity limit
FDA (Drugs) · 2025-08-13
- HighDirect Rx duloxetine 30 mg capsules exceed the interim nitrosamine limit
FDA (Drugs) · 2025-08-13
- ModerateCiprofloxacin Ophthalmic Solution Recalled for Defective Container Cap
FDA (Drugs) · 2025-04-23
- HighGeneric Ibuprofen 800mg Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-11-13
Same hazard · manufacturing defect
See all →- ModerateBoston Scientific Recalls Direxion Torqueable Microcatheters Due to Coating Defects
FDA (Devices) · 2026-10-28
- ModerateBoston Scientific Recalls Defective Direxion Torqueable Microcatheters
FDA (Devices) · 2026-10-28
- ModerateBoston Scientific Recalls Defective Direxion Torqueable Microcatheters
FDA (Devices) · 2026-10-28
- ModerateBoston Scientific Recalls Direxion Torqueable Microcatheters Due to Coating Defects
FDA (Devices) · 2026-10-28
- ModerateBoston Scientific Recalls Direxion Torqueable Microcatheters for Coating Defects
FDA (Devices) · 2026-10-28
Similar recalls
- ModerateDrug Recall: Simvastatin tablets due to manufacturing deviations
FDA (Drugs) · 2023-04-12
- ModerateSimvastatin 40 mg recalled nationwide for manufacturing quality deviations
FDA (Drugs) · 2023-05-10
- ModerateSimvastatin USP Tablets Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2023-05-10
- HighDrug recall: Simvastatin 20 mg due to manufacturing control deviations
FDA (Drugs) · 2023-05-10
- HighSimvastatin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-04-12
- HighPrescription Drug Simvastatin Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08